Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2021-07-16 Director's Dealing
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-07-16 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans and employee stock purchase plans. It includes detailed information about the securities to be registered, the plans under which they are offered, indemnification provisions, and exhibits related to corporate governance documents and consents. This type of filing is related to share issuance and capital changes, specifically for employee compensation plans. It is not an annual report, earnings release, or any other financial report but a registration statement for securities issuance. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the actual registration statement, not just an announcement or a certification, so SHA is the correct category with high confidence.
2021-07-16 English
Regulatory Filings 2021
Regulatory Filings
2021-07-16 English
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the offering, the registrant, and legal consents. This is a capital markets filing related to fundraising and securities registration, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 8313 characters, which is substantive and contains the registration details, not just an announcement or a certification.
2021-07-16 English
FWP
Capital/Financing Update Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433, relating to a Preliminary Prospectus dated July 12, 2021, for an initial public offering (IPO) of common stock by TScan Therapeutics, Inc. It includes details about the offering such as share count, pricing, dates, and underwriters. The document is a marketing communication supplementing the Preliminary Prospectus and is not a full financial report or regulatory filing like a 10-K or 10-Q. It is a type of prospectus used in securities offerings to provide additional information to investors. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is under 5,000 characters and is focused on the offering details, not a full report or announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2021-07-16 English
FORM 3 SUBMISSION
Director's Dealing
2021-07-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.